Tyra Biosciences tests innovative therapy in SURF302 for intermediate-risk bladder cancer

Tyra Biosciences tests innovative therapy in SURF302 for intermediate-risk bladder cancer
Tyra launches SURF302 bladder trial

Tyra Biosciences has launched the SURF302 clinical trial to assess a novel therapeutic strategy targeting intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC).

The study aims to address major treatment challenges associated with this type of bladder cancer, focusing on improving patient management and outcomes. The company is seeking to find new solutions to persistent obstacles in IR-NMIBC care, with further details about the trial available on its official website.

Tyra Biosciences recently intensified efforts to develop new therapies for urologic cancers, collaborating with experts and advocates as part of its research initiatives, as reported in a prior update. Earlier findings from the company linked FGFR3 gene changes to various cell growth disorders, affecting bone development and certain urologic cancers, according to company data. These prior studies contribute to the context for the current SURF302 clinical trial.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.